{"entity":{"type":"insider","cik":"0001792126","url":"/insider/0001792126","json_url":"/insider/0001792126.json","name":"Logos Global Management LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":3,"first":"2020-09-23","last":"2021-06-22","span_basis":"filed_date"},"name_variants":[{"name":"Logos Global Management LP","source":"filing","n_filings":3,"first_seen":"2020-09-23","last_seen":"2021-06-22"}],"transactions":[{"id":5087791,"accession":"0000899243-21-025313","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-025313","line_url":"/filing/0000899243-21-025313#line-2","is_derivative":false,"issuer_cik":"0001792126","issuer_name":"Verve Therapeutics, Inc.","issuer_ticker":"VERV","issuer_name_source":null,"issuer_url":"/issuer/0001792126","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":370000.0,"shares_display":"370,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":7030000.0,"total_display":"7,030,000.00","shares_owned_after":370000.0,"shares_owned_after_display":"370,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-21","filed_date":"2021-06-22","scope":"insider"},{"id":3151056,"accession":"0001567619-20-018886","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-9","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12942.0,"shares_display":"12,942","price_per_share":26.6442,"price_display":"26.64","price_state":"stated","total_value":344829.2364,"total_display":"344,829.24","shares_owned_after":187058.0,"shares_owned_after_display":"187,058","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151054,"accession":"0001567619-20-018886","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-8","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27.0,"shares_display":"27","price_per_share":27.02,"price_display":"27.02","price_state":"stated","total_value":729.54,"total_display":"729.54","shares_owned_after":199973.0,"shares_owned_after_display":"199,973","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151051,"accession":"0001567619-20-018886","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-7","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31000.0,"shares_display":"31,000","price_per_share":24.5299,"price_display":"24.53","price_state":"stated","total_value":760426.9,"total_display":"760,426.90","shares_owned_after":181000.0,"shares_owned_after_display":"181,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151049,"accession":"0001567619-20-018886","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-6","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":26.4824,"price_display":"26.48","price_state":"stated","total_value":397236.0,"total_display":"397,236.00","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151046,"accession":"0001567619-20-018886","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-5","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":26.174,"price_display":"26.17","price_state":"stated","total_value":392610.0,"total_display":"392,610.00","shares_owned_after":214973.0,"shares_owned_after_display":"214,973","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151045,"accession":"0001567619-20-018886","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-4","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12942.0,"shares_display":"12,942","price_per_share":25.879,"price_display":"25.88","price_state":"stated","total_value":334926.018,"total_display":"334,926.02","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151043,"accession":"0001567619-20-018886","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-3","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9098.0,"shares_display":"9,098","price_per_share":25.5507,"price_display":"25.55","price_state":"stated","total_value":232460.2686,"total_display":"232,460.27","shares_owned_after":224071.0,"shares_owned_after_display":"224,071","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151040,"accession":"0001567619-20-018886","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-2","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":24.0325,"price_display":"24.03","price_state":"stated","total_value":120162.5,"total_display":"120,162.50","shares_owned_after":150000.0,"shares_owned_after_display":"150,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":3151038,"accession":"0001567619-20-018886","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-20-018886","line_url":"/filing/0001567619-20-018886#line-1","is_derivative":false,"issuer_cik":"0001404281","issuer_name":"Novus Therapeutics, Inc.","issuer_ticker":"NVUS","issuer_name_source":null,"issuer_url":"/issuer/0001404281","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":25.973,"price_display":"25.97","price_state":"stated","total_value":103892.0,"total_display":"103,892.00","shares_owned_after":185000.0,"shares_owned_after_display":"185,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-30","filed_date":"2020-11-06","scope":"insider"},{"id":2045143,"accession":"0000899243-20-026189","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-026189","line_url":"/filing/0000899243-20-026189#line-2","is_derivative":false,"issuer_cik":"0001792126","issuer_name":"Dyne Therapeutics, Inc.","issuer_ticker":"DYN","issuer_name_source":null,"issuer_url":"/issuer/0001792126","owner_cik":"0001792126","owner_name":"Logos Global Management LP","owner_url":"/insider/0001792126","role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":700000.0,"shares_display":"700,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":13300000.0,"total_display":"13,300,000.00","shares_owned_after":1504392.0,"shares_owned_after_display":"1,504,392","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-21","filed_date":"2020-09-23","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":9,"open_market":true},{"code":"S","label":"Open-market sale","n":2,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001840574","name":"Verve Therapeutics, Inc.","url":"/issuer/0001840574","role":"Ten percent owner","n_filings":1,"first_seen":"2021-06-22","last_seen":"2021-06-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001404281","name":"Novus Therapeutics, Inc.","url":"/issuer/0001404281","role":"Ten percent owner","n_filings":1,"first_seen":"2020-11-06","last_seen":"2020-11-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001818794","name":"Dyne Therapeutics, Inc.","url":"/issuer/0001818794","role":"Ten percent owner","n_filings":1,"first_seen":"2020-09-23","last_seen":"2020-09-23"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001792126","retrieved_at":"2026-08-22T03:39:30+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}